Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Teva Pharmaceutical Industries Limited : The Klein Law Firm Reminds Investors of a Class Action Commenced on Behalf of Teva Pharmaceutical Industries Ltd. Shareholders and a Lead Plaintiff Deadline of October 23, 2017 (TEVA)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/04/2017 | 05:23pm CEST

NEW YORK, NY / ACCESSWIRE / October 4, 2017 / The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) who purchased American Depositary Shares between November 15, 2016 and August 2, 2017. The action, which was filed in the United States District Court for the Eastern District of Pennsylvania, alleges that the Company violated federal securities laws.

In particular, the complaint alleges that, throughout the Class Period, Defendants issued materially false and/or misleading statements and/or failed to disclose adverse information concerning the Company's business and outlook. In particular, it is alleged that Teva failed to disclose and/or omitted the true negative impact of the acquisition and integration of Actavis Generics on the Company's financial results and business prospects.

Shareholders have until October 23, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.

If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sbm/teva-pharmaceutical-industries-ltd?wire=1.

Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm


© Accesswire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TEVA PHARMACEUTICAL INDUST
10/21 TEVA PHARMACEUTICAL INDUSTRIES LIMIT : 3-DAY DEADLINE: Khang & Khang LLP Announc..
10/20 TEVA PHARMACEUTICAL INDUSTRIES LIMIT : DEADLINE MONDAY: Levi & Korsinsky, LLP Re..
10/19 TEVA PHARMACEUTICAL INDUSTRIES LIMIT : DEADLINE MONDAY: Lundin Law PC Announces ..
10/19 TEVA PHARMACEUTICAL INDUSTRIES : to Report Third Quarter 2017 Financial Results ..
10/19 TEVA PHARMACEUTICAL INDUSTRIES LIMIT : The Law Offices of Vincent Wong Reminds I..
10/19 TEVA PHARMACEUTICAL INDUSTRIES : Announces Submission of Biologics License Appli..
10/19 TEVA PHARMACEUTICAL INDUSTRIES : to Highlight New Data in Multiple Sclerosis at ..
10/18 TEVA REMINDER DEADLINE ALERT : The Law Offices of Howard G. Smith Reminds Invest..
10/18 TEVA PHARMACEUTICAL INDUSTRIES LIMIT : APPROACHING DEADLINE: Khang & Khang LLP A..
10/18 TEVA PHARMACEUTICAL INDUSTRIES LIMIT : Levi & Korsinsky, LLP Reminds Shareholder..
More news
News from SeekingAlpha
10/20 Debt-laden pharmas under pressure on Concordia's debt restructuring
10/19 J&J : Unattractive
10/18 TEVA BULLS ARE TOO EARLY : Debt Downgrade On The Way
10/18 YOUR DAILY PHARMA SCOOP : AZN's Imfinzi SBLA; Ablynx U.S. IPO; Is Teva A Buy?
10/18 HEALTHCARE DOGFIGHT : Owens & Minor Edges GlaxoSmithKline As Top Broker Pick For..
Financials ($)
Sales 2017 22 644 M
EBIT 2017 6 282 M
Net income 2017 -
Debt 2017 34 451 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 2,17x
EV / Sales 2018 2,06x
Capitalization 14 797 M
Chart TEVA PHARMACEUTICAL INDUST
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | TEVA | IL0006290147 | 4-Traders
Technical analysis trends TEVA PHARMACEUTICAL INDUST
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 28,0 $
Spread / Average Target 92%
Managers
NameTitle
Kåre Schultz President & Chief Executive Officer
Sol J. Barer Chairman
Carlo de Notaristefani President & CEO-Global Operations
Michael McClellan Chief Financial Officer
Michael R. Hayden Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
TEVA PHARMACEUTICAL INDUSTRIES LIMITED-62.38%14 797
JOHNSON & JOHNSON23.29%382 202
NOVARTIS13.50%226 404
PFIZER11.58%216 886
ROCHE HOLDING LTD.5.55%207 116
MERCK AND COMPANY7.88%174 223